|
Farhad Hafezi (born 1967 in Remscheid, Germany) is a Swiss eye surgeon and researcher. From 1994 until 2004 Hafezi was recognized as a leading researcher in the field of retinal degeneration, but in 2003 he began his research on the cornea, for which he is internationally known today. In the beginning of his research career, Hafezi was part of the team to discover the first gene that was responsible for light-induced retinal degeneration. Currently, Hafezi’s clinical and laboratory research is focused on ocular cell biology, and translational research initiatives like improving refractive eye laser surgery techniques and addressing complications. Hafezi is considered a leading expert and key opinion leader in the development and translation of corneal collagen cross-linking (CXL) and its multiple applications in the field of ophthalmology, including its application to treat corneal infection (PACK-CXL). Hafezi has published over 150 articles in various peer-reviewed scientific journals since 1997, including ''Nature Medicine, Nature Genetics, Investigative Ophthalmology & Visual Science'' and ''Cell Death & Differentiation.'' His most recent work in the field of corneal collagen cross-linking, has led him to receive a number of international awards. In 2014, his peers ranked Hafezi as one of the top 100 most influential people in ophthalmology. ==Early life and research== Hafezi was born in Remscheid, Germany in 1967, but he moved to Friborg, Switzerland in 1981. He studied medicine in Fribourg and Berne. Starting in 1993, Hafezi participated in a two year-course in experimental medicine and biology at the University of Zürich. After studying at the ETH Zürich, Hafezi spent 3 additional years at the University Hospital of Zurich. While at the University Hospital, he worked in the Laboratory for Retinal Cell biology, which was part of the Department of Ophthalmology. His studies in the Zürich laboratory, allowed Hafezi to identify the first known gene that could completely suppress light-induced retinal degeneration by apoptosis. The findings featured as a cover story in the April 1997 edition of ''Nature Medicine''. Following the findings, Hafezi focused on a number of areas of cell and cell and retinal degeneration. Between 1998 and 2000, two separate publications in journals were published, focusing on findings from his retinal degeneration research. The findings focused on light-induced cell death and the link to absent c-Fos. The findings featured in the journals ''Investigative Ophthalmology & Visual Science'' and ''Cell Death & Differentiation''. In 2000, the c-Fos research led to the discovery that c-Fos dependable mice could have the functions of c-Fos restored by using Fra-1. Fra-1 is part of the same Fos family of transcription factors as c-Fos, with the findings featuring in ''Genes & Development''. The findings were tested on mice in 2000, with results showing that c-Fos functions could be restored by using Fra-1 as a substitute. In the same year, Hafezi was part of a research group that identified RPE65 as essential for light-induced retinal degeneration. The article was published in ''Nature Genetics''. Hafezi further focused on light-induced cell death (apoptosis) of retinal photoceptors. In 2001, his work featured in ''Cell Death & Differentiation''. Later that year, he and a team of researchers developed a variation, which increased retinal resistance against light-induced degeneration by slowing rhodopsin regeneration. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Farhad Hafezi」の詳細全文を読む スポンサード リンク
|